Engflag

Mesalamine Suppositories

Quick links to important sections

Mesalamine Suppositories

Mesalamine Suppositories_DE

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mesalamine Suppositories

Property Description
Active ingredient Mesalamine (5-Aminosalicylic Acid / 5-ASA)
Form Suppository (Rectal dosage form)
Pharmacological class Aminosalicylate, Local Anti-inflammatory Agent
General purpose To mitigate inflammation and discomfort in the rectum
Origin Synthetic Derivative

Mesalamine Suppositories: Identity and Chemical Composition

Mesalamine Suppositories is a prescription-only medication containing the active ingredient Mesalamine, which is the non-proprietary chemical name for 5-Aminosalicylic Acid (5-ASA). The substance is classified within the Aminosalicylate drug class, functioning primarily as a highly effective anti-inflammatory agent. This compound is utilized for its specific efficacy in addressing inflammation within the lower gastrointestinal tract. As a single-ingredient product, Mesalamine is a synthetic derivative formulated in an inert, solid fatty base. Mesalamine is characterized by its anti-inflammatory properties focused on the gastrointestinal tract, which define its primary mechanism of action.

Pharmacological Classification and Targeted Rectal Form

The medication is specifically classified as a local-acting anti-inflammatory agent due to its targeted delivery via the rectal route of administration. It is manufactured as a suppository, a solid rectal dosage form unique for its localized action. The suppository form is typically reserved for managing inflammatory conditions concentrated in the rectum, providing a distinct advantage over oral forms designed for more extensive intestinal distribution. This specialized formulation ensures the active agent is delivered directly to the affected tissue in high concentration, facilitating localized management of the condition.

General Purpose of the Local Anti-Inflammatory Agent

The primary goal of using Mesalamine Suppositories is to soothe irritated tissue and reduce swelling by directly targeting the inflammatory processes in the rectum. The drug achieves this by interfering with the production of key inflammatory mediators, such as prostaglandins, within the rectal lining. This concentrated anti-inflammatory effect serves the general purpose of mitigating the localized symptoms of inflammation, including discomfort and redness, with the rectal dosage form intended to provide rapid, high-concentration relief specific to the rectal area.

What side effects are possible with Mesalamine Suppositories?

Possible side effects and safety information

Regulatory documents classify the potential effects of Mesalamine Suppositories by frequency and the body system involved. The profile includes expected common reactions, as well as documented serious adverse reactions (SARs) that are often rare but require specific consideration according to official labeling.

Common Adverse Reactions

Based on clinical trial data, effects classified as Common (occurring in ge 1% of patients) primarily affect the gastrointestinal and nervous systems. These frequently documented effects include headache, flatulence, abdominal pain, diarrhea, nausea, dizziness, and rectal pain. Other common reactions listed in regulatory texts are fever, rash, acne, and colitis.

Serious Adverse Reactions (SARs)

Official labeling specifically highlights the following clinically significant reactions, which are typically reported as rare or post-marketing:

  • Renal Impairment: This includes acute and chronic interstitial nephritis and renal failure. Official guidance recommends the evaluation of renal function before starting therapy and periodically thereafter.
  • Cardiovascular Effects: Documented SARs include myocarditis and pericarditis.
  • Acute Intolerance Syndrome: Symptoms may resemble an exacerbation of the underlying inflammatory condition, including cramping, acute abdominal pain, bloody diarrhea, fever, and headache.
  • Severe Cutaneous Adverse Reactions (SCARs): These are rare, potentially life-threatening skin reactions such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

Population and Safety Constraints

The medicine is contraindicated in individuals with known hypersensitivity to mesalamine, salicylates (including aspirin), or the suppository vehicle (Hard Fat, NF). Caution is officially advised for patients with pre-existing hepatic or renal impairment. Additionally, labeling notes an increased risk of blood dyscrasias in geriatric patients, recommending appropriate blood monitoring in this population. The product is also noted to cause photosensitivity.

Overdose and Emergency Response

Overdose and when to seek help

The officially documented information on mesalamine overdose is derived from its classification as an aminosalicylate, with anticipated manifestations resembling salicylate overdose (salicylism). The symptoms listed in regulatory documents include systemic effects such as tinnitus, headache, confusion, drowsiness, vomiting, and diarrhea.

Documented Overdose Manifestations and Actions

Classification Manifestations & Required Action
Severe Outcomes Life-threatening conditions documented include seizures, collapse, hyperthermia, and significant disruption of electrolyte balance or blood-pH imbalance.
Urgent Help Required Immediate medical attention is mandated if a person has seizures, trouble breathing, collapse, or cannot be awakened. Regulators advise contacting the regional poison control centre.
Antidote & Management No specific antidote is known for mesalamine overdose. Management is symptomatic and supportive, requiring hospital treatment, which often includes intravenous therapy to correct fluid imbalances. Close monitoring of renal function is a procedural requirement.

Official Regulatory Summary

This profile defines a risk of systemic toxicity that requires specific supportive measures due to the lack of a known antidote. The presence of life-threatening clinical signs establishes the threshold for immediate engagement with emergency services, as specified in regulatory guidance.

Therapeutic Uses of Mesalamine Suppositories

What Mesalamine Suppositories Treats: Main Uses and Benefits

This medication is primarily used to address conditions characterized by episodic or fluctuating manifestations where symptoms related to inflammatory or irritative states are confined to the rectum. It is commonly used across conditions presenting with acute episodes where the clinical goal is to induce remission (calm the active disease). The medication is applied in situations involving certain distressing symptoms linked to mild to moderately active ulcerative proctitis.

The treatment is applied across domains where additional symptomatic support is needed to address core manifestations. The medication is applied to ease challenging symptoms, such as rectal bleeding, diarrhea, and the painful, urgent sensation known as tenesmus.

“The treatment assists with maintaining functional stability when symptoms create noticeable physiological strain.”

This treatment is relevant for easing groups of symptoms that may become intense or disruptive, helping patients cope more steadily with difficult episodes. It contributes to improved day-to-day comfort during periods of heightened symptoms, supporting patients during difficult episodes by easing distress.

Quick Fact: Relief for Rectal Bleeding and Urgency

Eligibility and Restrictions for Use

Eligibility Scope

The use of Mesalamine Suppositories is indicated only for adults with mildly to moderately active ulcerative proctitis. Safety and effectiveness have not been established in pediatric patients, and use in children is generally not recommended or contraindicated in infants under two years of age by some regulators.

Contraindicated Populations

Mesalamine Suppositories are contraindicated in patients with a known or suspected hypersensitivity to salicylates (including aspirin), aminosalicylates (mesalamine), or any ingredient in the suppository vehicle [DailyMed; Source 1.4; Source 1.6].

Furthermore, some national regulatory documents list absolute contraindications for patients with severe renal impairment (GFR < 30 mL/ min/1.73 m^2) or severe hepatic impairment [Source 2.2].

Conditional Use and Restrictions

Patients with known renal or hepatic impairment require mandatory caution and close monitoring of organ function, and the risks must be evaluated against the potential benefits prior to and during treatment [Source 1.7; Source 2.4].

Regarding reproductive status, use during pregnancy and lactation is conditional. Regulatory documents advise that the medicine should be used only if the potential benefit outweighs the possible risk to the fetus or nursing infant [Source 1.3]. Infants should be monitored for the development of diarrhea [Source 1.1; Source 1.4].

Connection to the Overall Eligibility Profile

Official regulatory documents define the eligible population strictly by age, indication, and contraindication status. The drug is explicitly indicated only for adults, and non-negotiable exclusions are imposed for patients with confirmed hypersensitivity to the drug or its class. Conditional use guidelines mandate increased monitoring for patients with existing liver or kidney disease.

What should I know about interactions with other medicines?

Mesalamine Suppositories Interactions with other medicines and products

The regulatory labeling for mesalamine addresses specific interaction patterns that affect co-administered medicinal products and certain laboratory procedures. The suppository form's official profile focuses on clinically significant pharmacodynamic effects and analytical constraints, rather than extensive metabolic interactions.

Pharmacodynamic Interactions

Co-administration with Nephrotoxic Agents, which include medicines such as Non-Steroidal Anti-inflammatory Drugs (NSAIDs), is documented to increase the potential for nephrotoxicity (adverse effects on kidney function). Individuals with existing renal impairment are noted as a population where this interaction risk may be amplified.

The combined use of thiopurines, such as Azathioprine or 6-Mercaptopurine (6-MP), is associated with an increased risk of blood disorders, specifically myelosuppression. This is considered an additive pharmacological effect, and the official documents specify that mandatory monitoring of blood cell counts is required if these medicines are co-administered. Additionally, mesalamine may decrease the anticoagulant effect of Warfarin, a potential interaction that requires monitoring of the patient’s International Normalized Ratio (INR).

Procedural Constraints

Mesalamine and its metabolites are officially documented to interfere with laboratory testing. The drug may cause spuriously elevated test results when measuring urinary normetanephrine via liquid chromatography. This constraint necessitates the consideration of using an alternative, more selective analytical assay for diagnostic accuracy. The use of Mesalamine Suppositories is formally contraindicated in patients with a history of hypersensitivity to salicylates or aminosalicylates.

Mechanism of Action

How Mesalamine Suppositories Works

Local Reduction of Pro-inflammatory Mediators

Mesalamine (5-aminosalicylic acid, 5-ASA) acts primarily within the rectal lining by interacting with enzyme systems and signaling molecules. The drug engages mechanisms that suppress the synthesis and release of pro-inflammatory chemicals, specifically cytokines and eicosanoids (prostaglandins and leukotrienes), thereby reducing the local concentration of these mediators in the targeted tissue.

Targeted Enzyme Interference and Signaling Alteration

A core mechanistic domain involves interfering with the arachidonic acid cascade. Mesalamine directly inhibits specific enzymes, such as cyclooxygenase (COX) and potentially lipoxygenase (LOX), which are crucial for mediator synthesis. Modifying the activity of these pathways alters the signal transduction sequence downstream of the inhibited enzymes.

Oxidative Stress Reduction and Free Radical Scavenging

The drug also engages mechanisms that address oxidative stress. By acting as a free radical scavenger, mesalamine chemically neutralizes damaging reactive oxygen species (ROS) generated by immune cells. This action influences the chemical environment by reducing reactive oxygen species concentration within the tissue.

Dosage and Administration Information

How Mesalamine Suppositories is Used

Mesalamine Suppositories are administered strictly by the rectal route as a local treatment. This section outlines the standardized protocol for administration.

Administration Protocol and Dosing

Attribute Instruction
Route of Administration Rectal only
Standard Adult Dose One 1000 mg suppository rectally
Frequency Once daily
Timing Preferably at bedtime

Key Procedural Instructions

The administration of this medication involves several procedural steps:

  • Preparation: The foil or wrapper must be removed before insertion. It is recommended to empty the bowel just prior to using the suppository.
  • Retention: The suppository should be retained for one to three hours or longer, if possible, to maximize local tissue exposure.
  • Duration: The typical course of treatment for inducing remission is 3 to 6 weeks. Discontinuation should involve dose tapering where recommended, as abrupt cessation is not advised.
  • Missed Dose: If a dose is missed, it should be administered as soon as possible, unless it is almost time for the next scheduled dose. Do not use two suppositories at the same time to compensate for a missed dose.
  • Monitoring: The administration protocol includes the evaluation of renal function prior to initiating therapy and periodically throughout the treatment course.

This structured administration protocol defines the short-term use of the medication and is intended to support consistent application.

Recent Clinical Evidence

Mesalamine Suppositories: Recent Clinical Evidence

Evidence for Use in Inducing Remission of Ulcerative Proctitis

Research examined Mesalamine Suppositories primarily for conditions characterized by fluctuating or episodic manifestations—specifically, mild-to-moderately active ulcerative proctitis. A substantial part of the evidence comes from short-term, randomized controlled trials (RCTs). These studies were generally double-blind, involving a comparison between the suppository and an inactive treatment (placebo). Studies explored outcomes related to physical discomfort by tracking established scores for symptoms such as rectal bleeding, urgency, and the visual appearance of the rectal lining (mucosal healing).

Findings describe patterns observed in the studies over a typically short follow-up duration of four to eight weeks. The research provides insight into short-term changes, but these findings describe group patterns, not personal outcomes. Data remain insufficient regarding the extrapolation of findings beyond this initial observation period.

Research on Maintenance of Remission and Preventing Relapse

Research exploring long-term symptom patterns in proctitis is relevant for conditions presenting with cycles of stability and flare-ups. This involved longer-term randomized trials and systematic reviews exploring the sustained functional stability after the defined induction period. These studies monitored the rate of relapse (return of active symptoms) over defined time intervals, sometimes lasting from six months up to two years.

Studies reported measurements of how the long-term rate of relapse evolved in groups receiving the suppository compared to groups receiving an inactive treatment. Findings from systematic reviews often described patterns where the maintenance outcomes of the suppository formulation were measured against outcomes from oral mesalamine or mesalamine enemas, meaning the findings across those studies may have been mixed.

The Quality of Evidence and Areas of Uncertainty

The body of evidence examining short-term outcomes in adults with proctitis is often categorized as well-supported based on numerous, well-structured RCTs. For maintenance therapy, the evidence level is generally categorized as consistent for the suppository formulation specifically, due to limitations in direct head-to-head comparative evidence. Research highlights that findings often rely on extrapolation from adult studies for pediatric patients (children ages 5–17 years).

Key Studies & References

  1. MESALAMINE suppository: Official Drug Labeling Information and Approved Indications
  2. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis (2019)

Frequently Asked Questions (FAQ)

Common questions about Mesalamine Suppositories (FAQ)

Q: What should I do if I accidentally miss a dose?

Regulatory labeling indicates that if a dose is missed, it can be administered as soon as it is remembered. However, official information specifies that if it is almost time for the next scheduled dose, the missed one should be skipped. Official guidance specifies that two suppositories should not be used at the same time to compensate for a missed dose.

Q: Can I take this medication if I have kidney or liver problems?

Official labeling advises that patients with a history of kidney or liver impairment require caution and close monitoring of organ function before and during treatment. For those with severe renal or hepatic impairment, some regulators may indicate that the medication is contraindicated (not recommended for use). The evaluation of risks versus benefits is conducted by a healthcare provider.

Q: What common side effects should I watch out for?

Based on clinical trial data, common effects are usually related to the gastrointestinal or nervous systems. These frequently documented effects include headache, flatulence, and abdominal pain. Other common reactions listed in regulatory texts are diarrhea, nausea, dizziness, and rectal pain.

Q: What serious side effects are possible with this drug?

Official labeling highlights several rare but clinically significant reactions. Documented serious adverse reactions include reports of Renal Impairment (which affects kidney function) and inflammation of the heart (myocarditis and pericarditis). There is also a risk of Acute Intolerance Syndrome, which can present as a worsening of symptoms like abdominal pain and bloody diarrhea.

Q: What happens if I forget to store the suppositories in the fridge?

The official product label specifies that Mesalamine suppositories must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and must be protected from direct heat and light. The product must not be frozen. Some product labels may permit refrigeration, provided the specific temperature range is maintained.

Q: Can Mesalamine Suppositories be used for Crohn's disease?

Official product information specifies that the indication for this formulation is the treatment of mildly to moderately active ulcerative proctitis. Its use for other inflammatory bowel conditions, such as Crohn's disease, is not included in the approved indications.

Q: How long does it take for the suppository to start working and relieve symptoms?

Clinical studies indicate that initial improvement in symptoms, such as rectal bleeding, has been observed within the first week of therapy in some patients. Further improvement in other symptoms, like discomfort and urgency, has also been noted within two weeks of use.

Q: How do I know if I need to stop taking the suppositories?

Regulatory guidance indicates that use of the suppositories should be discontinued, and a healthcare professional should be contacted immediately, if certain symptoms occur. These include signs of a severe skin reaction (like blistering or peeling) or symptoms resembling an Acute Intolerance Syndrome, such as acute abdominal pain, bloody diarrhea, or fever.

How should Mesalamine Suppositories be stored and disposed of?

Storage and Disposal of Mesalamine Suppositories

Mesalamine suppositories must be stored at controlled room temperature, typically 20°C to 25°C (68 F to 77 F), as specified in regulatory labeling. It is mandatory to protect the medication from light and it must not be frozen. The product should always be stored out of the reach and sight of children to ensure safety.

Handling and Disposal

Suppositories should be kept in their original container. When disposing of unused or expired product, follow local requirements for pharmaceutical waste. Do not discard this medication by flushing it down the toilet or pouring it into a drain unless explicitly instructed by official guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Mesalamine Suppositories found in:

A-Z Index: